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phism is accumulating more rapidly than simple nucleotide vari-
ation. Also, restricted allelic diversity means that it is probable
that only nominal amino acid variation will occur in proteins
that are of potential immunoprophylaxis or virulence interest.
To gain further insight into the molecular evolutionary genetics
of M. tuberculosis, it will be necessary to determine the level of
sequence variation present in the other closely allied members
of the M. tuberculosis complex (M. bovis. Mycobacterium afri-
canum. and Mycobacterium microti) and the related slowly
growing pathogen Mycobacterium leprae. for which there is a
report of limited chromosomal diversity based on restriction en-
donuclease analysis [14].
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Colleagues-All treatments for cryptosporidial diarrhea to date
have given poor results, including the use of antidiarrheal, anti-
microbial, antiparasitic, and immunomodulatory compounds.
By contrast, aminosidine (paromomycin), a non-orally absorb-
able aminoglycoside antibiotic, was shown to be effective in vi-
tro at concentrations achievable in the bowel [I. 2] as well as in
experimentally infected animals [3]. Data from various patient
series and noncomparative trials have indicated that symptom-
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atic benefits and suppression of parasite growth are associated
with the use of oral aminosidine [I, 4-10].
Various aminoglycoside antibiotics belonging to the catenu-
lin group were marketed in the late 1950s and originally thought
to be separate entities. The identity of those compounds was
clarified later. Oral formulations ofaminosidine (paromomycin)
are available with different trade names, but the source of the
raw material is the same. Therefore, although referred to by
either name in the various publications, paromomycin and
aminosidine are synonymous.
On the basis of encouraging preliminary results and of the
availability of comprehensive information on the tolerability of
oral aminosidine for treating intestinal protozoan and helminth
infections, we set up a prospective, uncontrolled trial in human
immunodeficiency virus-infected patients with chronic crypto-
sporidial diarrhea.
Forty-one AIDS patients met the eligibility criteria (chronic
diarrhea caused by Crvptosporidium parvum, three or more
bowel movements per day, lasting for at least I month) and
received aminosidine (Gabbroral; Farmitalia Carlo Erba, Milan)
at 2000 mg for 4 weeks and at 1000 mg for the subsequent 4
weeks. No concomitant antidiarrheal or antiviral therapies were
allowed. Mean age was 31.2 years; most patients were male (n =
32) and intravenous drug users (n = 28). CD4 cell counts aver-
aged 39.3/mm3 (range, 4-208) at baseline and remained un-
changed during treatment.
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At the start of aminosidine treatment, I I patients had con-
comitant extraintestinal opportunistic infections, including
Pneumocystis carinii pneumonia, atypical disseminated myco-
bacteriosis, neurotoxoplasmosis, cerebral abscess, and bacterial
pneumonia; 3 had a concomitant intestinal parasitic infection
(en tarnebiasis, giardiasis, trichocephalosis) and 4 had gastrointes-
tinal bacterial infections (i.e., due to Helicobacter pylori, Proteus
species, Clostridium difficile. nontuberculous mycobacteria).
Thirty-five patients were deemed evaluatable for efficacy, and
22 (62.8%) completed the 8-week treatment course. The clinical
and parasitologic status improved dramatically in most patients
(table I).
With the initial dose, a complete response to therapy (parasi-
tologic plus clinical) was achieved in 7 (20%) of the 35 patients
in 7-28 days. The result was confirmed by duodenal biopsy and
remained consistently negative in 3 patients at 12 weeks of fol-
low-up. Of the remaining 4 patients, 2 relapsed parasitologically
and clinically after treatment discontinuation, and 2 recru-
desced when the dosage was reduced to 1000 mg/day.
An additional 15 patients (42.8%) had a partial response, 3
patients died, and 10 (28.5%) did not respond to the aminosi-
dine treatment (4 worsened, 6 showed inadequate response). Of
the latter, 2 had extraintestinal C. parvum infection. In no case
was death or treatment interruption attributed to the use of
aminosidine.
When the aminosidine dosage was reduced to 1000 rug/day,
symptoms gradually reappeared or increased in 9 of the 15 par-
tial responders and in 2 complete responders. Resumption of
the original dosage (2000 mg/day) in recrudescent patients for
28-42 days (mean, 31.6) restored the previous clinical status
and reduced the number of oocysts in the stools of 9 of the 17
patients. In the case of treatment failure, the addition of symp-
tomatic antidiarrheals (loperamide, octreotide) did not lead to
any substantial improvement.
Concomitant intestinal parasitic infections were also defini-
tively cured.
All responders had significantly better baseline conditions
than those who did not respond to therapy: CD4 cell counts
Table 1. Change from baseline in parasitologic and clinical pa-
rameters in patients receiving aminosidine therapy.
No. (%) of patients who
Remained
Parameter Worsened constant Improved
Bowel movements* 6(17.2) 3 (8.6) 26 (74.2)
Consistency of stool 6 (17.2) 6 (17.2) 23 (65.5)
Volume of stools 6 (17.2) 5(14.2) 24(68.6)
No. of oocysts" 3 (8.5) 8 (22.9) 24 (68.6)
Body weight 8 (22.9) 9 (25.7) 18 (51.4)
Abdominal pain 8 (22.9) 9(27.7) 18 (51.4)
Nausea or vomiting 5 (14.2) 8 (22.9) 22 (62.9)
* Ten patients had normal bowel movements after a mean of 5.3 days of
therapy (range. 3-18): 6 reported constipation (one movement every sec-
ond or third day) after a mean of6.1 (5-16) days of treatment with 2 g/day.
t Mean/TO microscopic fields X 1000 (modified Ziehl-Nielsen staining).
Ten patients cleared oocysts after a mean of-l8.6 days of therapy; complete
parasitologic cure was confirmed in 3 by duodenal biopsy at 12 weeks of
follow-up.
> 150/mm3, mean of four or fewer bowel movements/day, ~5
oocysts/rnicroscopic field X 1000.
Treatment was well tolerated: 6 patients reported transient
constipation on the higher dosage. No significant change was
observed in the clinical laboratory parameters. -
Like prior studies, the present trial has limitations due to the
open, uncontrolled nature of the trial and the relatively small
size. However, the results indicate a role for aminosidine in
cryptosporidial diarrhea and are substantiated by a randomized,
placebo-controlled study [8].
Consistent with findings in other patients, administration of
aminosidine was associated in most patients with suppression of
parasite growth rather than killing, and the effect was dose-re-
lated. Some patients with less advanced disease and lower para-
site load were definitively cured, thus indicating the advantage
of early diagnosis and intervention and suggesting a possible
preventive role of aminosidine for cryptosporidiosis [3]. More-
over, the broad spectrum of activity, encompassing protozoa
and helminths, makes aminosidine a drug of potential interest
for wide coverage of noninvasive intestinal parasitic infections
in immunocompromised patients.
M. Scaglia, C. Atzori, G. Marchetti, M. Orso, R. Maserati,
A. Orani, S. Novati, and P. Olliaro*
Institute for Infectious Diseases. University-lRCcS S. Matteo. Pavia,
Infectious Diseases Unit. Busto Arsizio, Infectious Diseases Unit. Ca
Granda Hospital. Milan. and Infectious Diseases Unit, Lecco, Italy
* Present affiliation: United Nations Development Programme/World
Bank/World Health Organization Special Programme for Research and
Training in Tropical Diseases. Geneva.
References
I. Datry A. Rogeaux O. Caurnes E. et al. Effects ofaminosidine sulfate on
Crvptosporidium in cell culture and in AIDS patients [abstract P175].
In: Proceedings of the 3rd European Conference on HIV Infection,
Paris. 1992.
2. Marshall RJ. Flanigan TP. Paromomycin inhibits Cryptosporidium in-
fection ofa human enterocyte cell line. J Infect Dis 1992; 165:772-4.
3. Fayer R. Ellis W. Paromomycin is effective as prophylaxis for crypto-
sporidiosis in dairy calves. J Parasitol 1993;79:771-4.
4. Clezy K. Gold J. Blaze J. Jones P. Paromomycin for the treatment of
cryptosporidial diarrhoea in AIDS patients. AIDS 1991;5: 1146-7.
5. Drake J. Olliaro P. Catterall L. et al. Efficacy and tolerability of oral
aminosidine (Gabbroral) for the treatment of cryptosporidial
diarrhoea in patients with AIDS. AIDS 1992;6(suppl I ):P45. S27.
6. Armitage K. Flanigan T. Carey J. et al. Treatment of cryptosporidiosis
with paromomycin. A report of five cases. Arch Intern Med
1992: 152:2497-9.
7. Fichtenbaum CJ. Ritchie DJ. Powderly GW. Use of paromomycin for
treatment of cryptosporidiosis in patients with AIDS. Clin Infect Dis
1993; 16:298-300.
8. Kanyok TP. Novak RM, Danziger LH. Preliminary results ofa random-
ized. blinded. control study ofparomomycin vs. placebo for the treat-
ment of Crvptosporidium diarrhea in AIDS patients [abstract PoBIO-
1508]. In: Program and abstracts: IX International Conference on
AIDS (Berlin). London: Wellcome Foundation. 1993.
9. Wallace MR, Nguyen MT. Newton JA. Use of paromomycin for the
treatment of cryptosporidiosis in patients with AIDS. Clin Infect Dis
1993; 17: 1070-1.
10. Bissuel F. Corte L. Rabodonirina M, Rougier p. Piens MA, Trepo C.
Paromomycin: an effective treatment for cryptosporidial diarrhea in
patients with AIDS. Clin Infect Dis 1994; 18:447-9.
